Michael Giordano
Director/Board Member chez RAPT THERAPEUTICS, INC.
Fortune : 58 329 $ au 31/03/2024
Profil
Michael F.
Giordano is currently an Independent Director at Rapt Therapeutics, Inc., a Non-Executive Director at Achilles Therapeutics UK Ltd., a Director at Oncovalent Therapeutics, Inc., and an Independent Non-Executive Director at Achilles Therapeutics Plc.
Previously, he served as a Director at Epizyme, Inc. from 2018 to 2022 and as the Senior Vice President & Head-Oncology Development at Bristol Myers Squibb Co. from 2012 to 2017.
He also held positions as an Assistant Professor at the National Institutes of Health and Weill Cornell Medicine.
He obtained his undergraduate degree from The Johns Hopkins University and his doctorate from Weill Cornell Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/02/2023 | 46 663 ( 0,11% ) | 58 329 $ | 31/03/2024 | |
RAPT THERAPEUTICS, INC.
-.--% | 28/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Michael Giordano
| Sociétés | Poste | Début |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Director/Board Member | 01/01/2018 |
| ACHILLES THERAPEUTICS PLC | Director/Board Member | 01/09/2018 |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | 19/09/2018 |
Oncovalent Therapeutics, Inc.
 Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncovalent Therapeutics, Inc. develops immuno oncology drugs and therapeutics. The company is based in Thousand Oaks, CA. Pete Feldman has been the CEO of the company since 2020. | Director/Board Member | - |
Anciens postes connus de Michael Giordano
| Sociétés | Poste | Fin |
|---|---|---|
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | 01/08/2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/02/2017 |
| Weill Cornell Medicine | Corporate Officer/Principal | - |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Formation de Michael Giordano
| The Johns Hopkins University | Undergraduate Degree |
| Weill Cornell Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| RAPT THERAPEUTICS, INC. | Health Technology |
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Oncovalent Therapeutics, Inc.
Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncovalent Therapeutics, Inc. develops immuno oncology drugs and therapeutics. The company is based in Thousand Oaks, CA. Pete Feldman has been the CEO of the company since 2020. | Health Technology |
